Navigation Links
Viteava Pharmaceuticals Executes Worldwide Exclusive License
Date:11/19/2013

TORONTO, Nov. 19, 2013 /PRNewswire-iReach/ -- Viteava Pharmaceuticals Inc. announced the execution of an exclusive worldwide license to an intellectual property portfolio claiming composition of matter and/or methods of use of novel analogs and derivatives of the green tea flavonoid, (-)epigallocatechin-3-gallate (EGCG). This intellectual property resulted from a long-standing collaboration between Professor Tak-Hang Chan of McGill University and the Hong Kong Polytechnic University, and Professor Q. Ping Dou of Wayne State University and the Karmanos Cancer Institute. The intellectual property portfolio is owned by McGill University, Wayne State University, the University of South Florida, the Moffitt Cancer Center, and the Hong Kong Polytechnic University. Patents have been issued in the U.S., Japan and China and are pending in other international jurisdictions.

(Photo: http://photos.prnewswire.com/prnh/20131119/MN19612)

Viteava Pharmaceuticals is a privately-held start-up drug development company established to commercialize this intellectual property portfolio. "Negotiating and executing this license agreement with multiple leading institutions was an important achievement and critical to advancing several exciting drug candidates discovered in the academic setting," said Robert Foldes, Viteava's founder and CEO.

"I am very excited to work together with Viteava Pharmaceuticals to move towards the clinic drug candidates designed through a deep understanding of structure-activity relationships involving the EGCG pharmacophore that my laboratory has researched for many years," said Professor Chan. "We have been working diligently to translate the well-established health benefits of green tea and its major active ingredient, EGCG, to design commercially-viable drug candidates."

Viteava Pharmaceuticals will focus on the development of novel approaches to manage cancer and related conditions. It has identified VPE001, a prodrug of EGCG with improved bioavailability and potency, as its lead drug candidate expected to enter clinical development in 2015. Initial clinical indications may include the treatment of uterine fibroids and/or delaying the progression of cancer in high-risk, early-stage chronic lymphocytic leukemia patients.

Professor Dou added, "My laboratory was the first to identify inhibition of proteasomal chymotrypsin-like activity as an important mechanism of action of EGCG. We also know that EGCG can also affect, albeit to a lesser extent, other important pathways, such as PI3K/Akt/mTOR signaling. Viteava's drug candidates target diseases where these pathways are dysregulated."

The company's strategy focuses principally on clinical indications where green tea extracts have been demonstrated to elicit biological responses in human studies. Viteava's drug candidates are designed to improve these treatment regimens and achieve better clinical outcomes, while retaining a high level of safety. By regulating multiple pathways important to the progression of diseases such as cancer, Viteava's drug candidates are expected to provide advantages over more potent and more selective drugs that usually only elicit temporary responses together with a high level of toxicity.

Robert Foldes added that "our strategy certainly reduces clinical development risk while targeting significant medical conditions lacking efficacious long-term pharmaceutical interventions and where we can significantly improve standard-of-care."

About Viteava Pharmaceuticals Inc.

Viteava is a start-up drug development company dedicated to improving the treatment and management of cancer and related conditions to enhance quality of life. It is a world leader in the chemistry and biology of small molecule analogs and derivatives related to the green tea flavonoid, (-)epigallocatechin-3-gallate (EGCG). Its mission is to leverage the growing body of positive human clinical data with green tea extracts, to develop novel chemical entities with enhanced potency and bioavailability, ideally suited to early intervention in the treatment and management of cancer and related conditions.

For more information visit: http://www.viteava.com.

Media Contact: Robert Foldes, Viteava Pharmaceuticals Inc., 416-817-0745, robert@viteava.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Viteava Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biotest Pharmaceuticals Honored with the 2013 Greater Miami Chamber of Commerce International Business Leadership Award for "Business Expansion"
2. GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results
3. Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
4. Hi-Tech Pharmaceuticals Sues The FDA For "Bullying Tactics"
5. GW Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
6. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
7. RXi Pharmaceuticals Corporation and Ethicor Ltd. Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
8. Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
9. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
10. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
11. ANI Pharmaceuticals To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- NOIT™ Research LLC, a private, leading-edge autism research group, ... assist needy families in obtaining one of its special ... 10, 2016 and March 31, 2016, the company will ... is an auditory stimulus that plays a key role ... Beth Shier , NOIT Research director. "The ...
(Date:2/11/2016)... N.C. , Feb. 11, 2016 ... leading provider of custom manufacturing and development services ... expanded sterile fill-finish capabilities and capacity in its ... growth in demand has driven several recent investments. ... 2001 it had one filling line with small-scale ...
(Date:2/11/2016)... Ore. , Feb. 11, 2016 Wellpartner, ... announce the acquisition of SolutionsRx, a full-service 340B company ... Along with providing traditional contract pharmacy services, SolutionsRx also ... clients in navigating the complex 340B regulatory environment. ... --> James R. Love , CEO of ...
Breaking Medicine Technology:
(Date:2/12/2016)... , ... February 12, 2016 , ... The law firm ... and Evangeline Parishes. The purpose of these scholarships is to encourage applicants to ... individuals to seek employment within these two parishes. , “We have available jobs ...
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections ... Center. Almost 10,000 physical therapists across the country are expected to attend this annual ... chosen field and network with their colleagues. As in years past, HydroWorx is ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a ... offer real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... ... 2016 , ... Vail knee specialist Robert LaPrade, MD, PhD was ... The list consists of physicians establishing, leading and partnering with ambulatory surgery centers across ... Ambulatory Surgery Center, also known as an ASC, is a modern health care facility ...
(Date:2/12/2016)... ... 2016 , ... For Coast Dental dentist Everet Lake, DDS, the smiles began ... Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry from the Heart event ... skills to help hundreds of uninsured and underinsured people receive much-needed dental care. ...
Breaking Medicine News(10 mins):